Surgical timing following neoadjuvant chemotherapy for breast cancer affects postoperative complication rates

被引:18
|
作者
Sutton, Thomas L. [1 ]
Johnson, Nathalie [2 ]
Schlitt, Alexander [3 ]
Gardiner, Stuart K. [4 ]
Garreau, Jennifer R. [2 ]
机构
[1] Oregon Hlth & Sci Univ, Dept Surg, 3181 Sw Sam Jackson Pk Rd, Portland, OR 97239 USA
[2] Legacy Canc Inst, Legacy Med Grp Surg Oncol, 1040 NW 22nd Ave,Suite 560, Portland, OR 97227 USA
[3] Pacific Northwest, Coll Osteopath Med, 200 Mullins Dr, Lebanon, OR 97355 USA
[4] Legacy Hlth, Legacy Res Inst, Devers Eye Inst, 1225 NE 2nd Ave, Portland, OR 97232 USA
来源
AMERICAN JOURNAL OF SURGERY | 2020年 / 219卷 / 05期
关键词
Complications; Breast cancer; Time to surgery; Neoadjuvant chemotherapy; ANTINEOPLASTIC AGENTS; IMPACT; CYCLOPHOSPHAMIDE; SURGERY; DOXORUBICIN; ADRIAMYCIN; MASTECTOMY; DOCETAXEL; OUTCOMES; TIME;
D O I
10.1016/j.amjsurg.2020.02.061
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Neoadjuvant chemotherapy (NAC) is increasingly used in the treatment of breast cancer. The time interval from last dose of cytotoxic chemotherapy to surgery (TTS) can vary widely. We aimed to evaluate the effect of TTS on postoperative complications. Methods: A retrospective review for women treated with NAC at our institution between January 2011 through December 2016 was performed. Charts were reviewed for postoperative wound complications, and multivariate analysis was performed. Results: 455 patients were identified. Median TTS was 30 days (range 11-228). On multivariate analysis, TTS of less than 28 days was associated with 70% higher odds of any wound complication (p < 0.05). Increasing age had the strongest association with the presence of any wound complication (p < 0.0001). The majority of complications were treated in the outpatient setting (n = 80, 83%). Conclusion: Following NAC for breast cancer, TTS less than 28 days is a risk factor for postoperative wound complications; however, the majority of complications are minor and treated in the outpatient setting. Additional data are needed to determine optimal TTS for oncologic outcomes. (C) 2020 Published by Elsevier Inc.
引用
收藏
页码:741 / 745
页数:5
相关论文
共 50 条
  • [41] Trends in Neoadjuvant Chemotherapy for Surgical Breast Cancer Patients in the United States
    Schoellhammer, H. F.
    Streja, L.
    Kruper, L.
    Vito, C.
    Yim, J.
    Chen, S. L.
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 : S57 - S57
  • [42] Impact of Imaging After Neoadjuvant Chemotherapy on Surgical Management of Breast Cancer
    Breese, Rebecca
    Pu, Tracey
    Arif, Fatima
    Bennett, Stephanie
    Reed, Jennifer
    Friend, Kara
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 2) : S429 - S430
  • [43] Surgical Wound Complications in Breast Cancer Patients After Neoadjuvant Chemotherapy
    Miah, Pabel
    Pourkey, Nakisa
    Marmer, Alyssa
    Sevdalis, Athanasios
    Amburn, Thomas
    Pak, Linda
    Shapiro, Richard
    Hiotis, Karen
    Axelrod, Deborah
    Guth, Amber
    Schnabel, Freya
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 2) : S354 - S355
  • [44] Impact of Progression During Neoadjuvant Chemotherapy on Surgical Management of Breast Cancer
    Caudle, Abigail S.
    Gonzalez-Angulo, Ana M.
    Hunt, Kelly K.
    Pusztai, Lajos
    Kuerer, Henry M.
    Mittendorf, Elizabeth A.
    Hortobagyi, Gabriel N.
    Meric-Bernstam, Funda
    ANNALS OF SURGICAL ONCOLOGY, 2011, 18 (04) : 932 - 938
  • [45] Impact of Progression During Neoadjuvant Chemotherapy on Surgical Management of Breast Cancer
    Abigail S. Caudle
    Ana M. Gonzalez-Angulo
    Kelly K. Hunt
    Lajos Pusztai
    Henry M. Kuerer
    Elizabeth A. Mittendorf
    Gabriel N. Hortobagyi
    Funda Meric-Bernstam
    Annals of Surgical Oncology, 2011, 18 : 932 - 938
  • [46] Pathologic Response Rates Following Neoadjuvant Anthracycline and Taxane-based Chemotherapy for Early Breast Cancer (EBC)
    Redana, S.
    Papadimitraki, E.
    Mohammed, K.
    Lote, H.
    Sharp, A.
    Capelan, M.
    CLINICAL ONCOLOGY, 2017, 29 (06) : E103 - E103
  • [47] Effect of breast conservation following neoadjuvant chemotherapy vs mastectomy with adjuvant chemotherapy in operable breast cancer
    Orozco, Javier
    Nelson, Daniel
    Chang, Shu-Ching
    Goldfarb, Melanie
    Holmes, Dennis
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : 341 - 342
  • [48] Surgical-Decision Making Following Neoadjuvant Chemotherapy in Primary Breast Cancer: A Single-Centre Study
    Badakhshan, Uashar
    Kaur, Princee
    Hubbard, Tom
    BJS-BRITISH JOURNAL OF SURGERY, 2025, 112 : 20 - 20
  • [49] Novel Applications of Cross-Sectional Imaging in Oncoplastic Surgical Planning for Breast Cancer Following Neoadjuvant Chemotherapy
    Begaj, A.
    McLean, R.
    Bhaskar, P.
    BRITISH JOURNAL OF SURGERY, 2021, 108 : 69 - 69
  • [50] Histopathologic changes following neoadjuvant chemotherapy in locally advanced breast cancer
    Sethi, D.
    Sen, R.
    Parshad, S.
    Khetarpal, S.
    Garg, M.
    Sen, J.
    INDIAN JOURNAL OF CANCER, 2013, 50 (01) : 58 - 64